| | 
Part, Chapter, Paragraph
1 I, 3. 3 | population growth in the E.U. leads to shifts in the
2 I, 3. 4 | References~ ~Beets G, Dourleijn E, Liefbroer A, Henkens K (
3 I, 3. 4 | NIDI, Den Haag.~ ~Bloom D E, Trussell J (1984): What
4 I, 3. 4 | infecondité en Europe, in A. Blum e J. L. Rallu (eds) Démographie
5 II, 5. 2. 7| S1-16.~Puska P, Vartiainen E, Tuomilehto J, Salomaa V,
6 II, 5. 2. 7| M, Tolonen H, Ruokokoski E, Amouyel P (1999): Contribution
7 II, 5. 3. 9| Baili P, Quinn M, Mugno E, Capocaccia R, Grosclaude
8 II, 5. 3. 9| Micheli A, Berrino F, Paci E, Verdecchia A, Pierotti
9 II, 5. 3. 9| Capocaccia R, Martinez C, Mugno E, Coebergh JW, Baili P, Verdecchia
10 II, 5. 4. 8| Lapetra ML, Wei L, Kelley E and the Members of the HCQI
11 II, 5. 4. 8| 421-7~Pruna S, Stanciu E, Macarie A, Pruna A, Ionescu-Tirgoviste
12 II, 5. 5. 3| C, Schulze B, Bertocchi E, Rossi G, Ghilardi A, Pioli
13 II, 5. 5. 3| Nakonezny PA, Lescouflair E (2007): Antipsychotic medication
14 II, 5. 5. 3| 2nd edition - Jané-Llopis E, Anderson P eds.).~Fang
15 II, 5. 5. 3| Knapp M, McDaid D, Mossialos E, Thornicroft G (2007): Mental
16 II, 5. 5. 3| Psychiatry 188:193.~Lindström E, Eberhard J, Neovius M,
17 II, 5. 5. 3| S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach
18 II, 5. 5. 3| Silverstone T, Smith G, Goodall E (1988): Prevalence of obesity
19 II, 5. 5. 3| Reports, Nov-Dec.~Fombonne E (2005): Epidemiology of
20 II, 5. 5. 3| Disabilities, London.~Sánchez-Valle E et al (2007): Estimating
21 II, 5. 5. 3| Epilepsia 21:235-242.~Beghi E, Cornaggia CM, and the RESt-1
22 II, 5. 5. 3| Epilepsia 43:1076-1083.~Beghi E (2004): Aetiology of epilepsy.
23 II, 5. 5. 3| Edited by: Shorvon S, Perucca E, Fish D, Dodson E.) Oxford,
24 II, 5. 5. 3| Perucca E, Fish D, Dodson E.) Oxford, Blackwell Science;
25 II, 5. 5. 3| Science; p. 50-63.~Beghi E, Sander JW (2005): Epilepsy
26 II, 5. 5. 3| Edited by: Shorvon S, Perucca E, Fish D, Dodson E.) Oxford,
27 II, 5. 5. 3| Perucca E, Fish D, Dodson E.) Oxford, Blackwell Science;
28 II, 5. 5. 3| 21-42.~Forsgren L, Beghi E, Oun A, Sillanpaa M (2005):
29 II, 5. 5. 3| suppl 11):S15-S19.~Olafsson E, Hauser WA, Gudmundsson
30 II, 5. 5. 3| Epilepsia 39:89-92.~Olafsson E, Ludvigsson P, Gudmundsson
31 II, 5. 5. 3| 239-148.~Tomson T, Beghi E, Sundqvist A, Johannessen
32 II, 5. 5. 3| Van den Broek M, Beghi E, for the RESt-1 group (2004):
33 II, 5. 5. 3| 210.~Benito-Léon J, Martín E, Vela L et al (1998): Multiple
34 II, 5. 5. 3| Deomina T, Favorova O, Gusev E, Sudomoina M, Turetskaya
35 II, 5. 5. 3| Koch-Henriksen N, Stenager E (2004): Trends in survival
36 II, 5. 5. 3| Brønnum-Hansen H, Stenager E, Hansen T, Koch-Henriksen
37 II, 5. 5. 3| Lancet 7;268-277.~Ekestern E, Lebhart G (2004). Mortality
38 II, 5. 5. 3| 1033–1040.~Ford HL, Gerry E, Airey CM, et al (1998):
39 II, 5. 5. 3| 605–610.~Ford HL, Gerry E, Johnson M, Williams R (
40 II, 5. 5. 3| Accessed June 14 2005.~Granieri E, Malagú S, Casetta I, et
41 II, 5. 5. 3| 186.~Grønlie SA, Myrvoll E, Hansen G, et al (2000):
42 II, 5. 5. 3| N, Rasmussen S, Stenager E, et al (2001). The Danish
43 II, 5. 5. 3| 185.~Mor u T, eaManceau E, Lucas B, Lemesle M, Urbinelli
44 II, 5. 5. 3| Ranzato F, Perini P, Tzintzeva E et al (2003): Increasing
45 II, 5. 5. 3| Aarsland D, Larsen JP, Tandberg E, Laake K (2000): Predictors
46 II, 5. 5. 3| P, Maggi S, Perissinotto E, Grigoletto F, Amaducci
47 II, 5. 5. 3| Bergareche A, De La Puente E, Lopez de Munain A, Sarasqueta
48 II, 5. 5. 3| CE, Zobkiw RM, Gullaksen E (1995): Quality of life
49 II, 5. 5. 3| R, Gamberini G, Granieri E, Benassi G, Naccarato S,
50 II, 5. 5. 3| Szucs T, Rathay B, Scholz E, Oertel WH (1998): The economic
51 II, 5. 5. 3| Privaten Krankenversicherung e 46(4):122-128.~Elbaz A,
52 II, 5. 5. 3| 217(2):169-174.~Granieri E, Carreras M, Casetta I,
53 II, 5. 5. 3| Govoni V, Tola MR, Paolino E, Monetti VC, De Bastiani
54 II, 5. 5. 3| 339.~Horstink M, Tolosa E, Bonuccelli U, Deuschl G,
55 II, 5. 5. 3| Campenhausen S, Spottke E, Siebert U, Dodel R (2005):
56 II, 5. 5. 3| 264.~Rosati G, Granieri E, Pinna L, Devoto MC (1979):
57 II, 5. 5. 3| 308.~Rosati G, Granieri E, Pinna L, Aiello I, Tola
58 II, 5. 5. 3| Brain 123:2297-2305.~Singer E (1973): Social costs of
59 II, 5. 5. 3| Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M (
60 II, 5. 6. 6| References~ ~Altman R, Asch E, Bloch D, Bole G, Borenstein
61 II, 5. 6. 6| Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen
62 II, 5. 6. 6| Arthritis Rheum 41:778-799~Levy E, Ferme A, Perocheau D, Bono
63 II, 5. 6. 6| Goldsmith CH, Jamieson E, Torrance GW, Tugwell P (
64 II, 5. 6. 6| Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman
65 II, 5. 6. 6| D, Veale DJ, Martin-Mola E (2004): Musculoskeletal
66 II, 5. 6. 6| 1st ed. (Edited by Nancy E Lane and Philip N Sambrook)
67 II, 5. 7. 7| Claris-Appiani A, Taioli E, et al (2003): Epidemiology
68 II, 5. 7. 7| 106(6):703-10.~Ejerblad E, Fored CM, Lindblad P, Fryzek
69 II, 5. 7. 7| Netherlands, June 2007.~Esbjorner E, Berg U, Hansson S (1997):
70 II, 5. 7. 7| 1047.~Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004):
71 II, 5. 7. 7| Bindman AB, Vittinghoff E, Kanaya AM, Kushel MB (2007):
72 II, 5. 8. 7| Moreau D, Kalaboka S, Gay E, Bonnefoy X, Carrozzi L,
73 II, 5. 8. 7| Nizankowska-Mogilnicka E, on behalf of BOLD Collaborative
74 II, 5. 8. 7| 424.~ ~Furhman C, Jougla E, Nicolauu J, Eilstein D,
75 II, 5. 8. 7| M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski
76 II, 5. 8. 7| G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum
77 II, 5. 8. 7| Hallin R, Ulrik CS, Brondum E,Nieminen MM, Aine T, Bakke
78 II, 5. 8. 7| Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM (2006):
79 II, 5. 8. 7| Borg S, Ericsson A, Jonsson E, Lundback B (2002): Costs
80 II, 5. 8. 7| Johannessen A, Omenaas E, Bakke P, Gulsvik A (2005):
81 II, 5. 8. 7| Bjerg-Backlund A, Ronmark E, Larsson LG, Lundback B. (
82 II, 5. 8. 7| Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG,
83 II, 5. 8. 7| Eriksson B, Larsson LG, Ronmark E, Sandstrom T, Lundback B (
84 II, 5. 8. 7| A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E,
85 II, 5. 8. 7| Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S,
86 II, 5. 8. 7| J, Montemayor T, Gobartt E, Martin A, Alvarez-Sala
87 II, 5. 8. 7| 349: 1498–1504.~ ~Murtagh E, Heaney L, Gingles J, Shepherd
88 II, 5. 8. 7| 20: 443-453.~Niederlander E. Health (2006): In “Population
89 II, 5. 8. 7| Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling
90 II, 5. 9. 7| 7, 954-960~ ~Compalati E, Penagos M, Henley K, Canonica
91 II, 5. 9. 7| Erwin EA, Custis N, Ronmark E, Wickens K, Sporik R, Woodfolk
92 II, 5. 9. 7| Holgate ST, Price D, Valovirta E (2006): Asthma out of control?
93 II, 5. 9. 7| Bettoncelli G, Cricelli C, Sessa E, Mazzaglia G, Canonica GW,
94 II, 5. 9. 7| 62(5):569-71)~ ~Migliore E (2007): Prevalence of respiratory
95 II, 5. 10.Acr| Diseases~IgE~Immunoglobulin E~SCF~Scientific Committee
96 II, 5. 10. 5| Nuts and products thereof (e)~- Celery and products thereof~-
97 II, 5. 10. 5| beverages; lactitol.~ ~(e) nuts used for making distillates
98 II, 5. 10. 7| allergen-specific immunoglobulin E antibodies from 1973 to
99 II, 5. 10. 7| press):~Mills EN, Valovirta E, Madsen C, Taylor SL, Vieths
100 II, 5. 10. 7| Taylor SL, Vieths S, Anklam E, Baumgartner S, Koch P,
101 II, 5. 10. 7| Frewer L, Madsen C, Botjes E, Crevel RWR, van Ree R (
102 II, 5. 10. 7| D, Zuidmeer L, Sodergren E, Sigurdardottir S, Lindner
103 II, 5. 10. 7| Feighery C, Janssen FW, Méndez E, Mothes T, Troncone R, Wieser
104 II, 5. 11. 3| around 30% (L Dotterud and E Falk, 1994). In Finland,
105 II, 5. 11. 3| years of age (L Dotterud and E Falk, 1994). Sensitivity
106 II, 5. 11. 3| 2007;388:24-34.~L Dotterud, E Falk, Metal allergy in north
107 II, 5. 11. 3| R, Turjanmaa K, Varjonen E, Vuorela AM, Patch test
108 II, 5. 11. 3| F Pere a, O Bord o, E Silva, A Barr , M Gonç ,
109 II, 5. 11. 7| 89:1121–1133.~ ~De Vries E, Bray FI, Coebergh JW, Parkin
110 II, 5. 12. 7| Lucchini F, Zatonski WA, Negri E, La Vecchia C (2007): Worldwide
111 II, 5. 12. 7| 389.~de la Pena J, Brullet E, Sanchez-Hernandez E, Rivero
112 II, 5. 12. 7| Brullet E, Sanchez-Hernandez E, Rivero M, Vergara M, Martin -~ ~
113 II, 5. 12. 7| Lucchini F, Franceschi S, Negri E (1994): Worldwide patterns
114 II, 5. 12. 7| Available at: htt ~ ~Negri E, Little D, Boiocchi M, La
115 II, 5. 14. 2| Number of adults surveyed.~ ~e. Dentists and Other Oral
116 II, 5. 14. 8| http://www.who.int/gb/e/e_wha60.html] (article online,
117 II, 5. 14. 8| http://www.who.int/gb/e/e_wha60.html] (article online,
118 II, 6. 3. 2| intestinal bacteria enterococci, E. coli, Klebsiella pneumoniae,
119 II, 6. 3. 2| aeruginosa, enterobacteriaceae (E. Coli, Enterobacter, Klebsiella),
120 II, 6. 3. 3| of viral hepatitis in the E.U.~ ~Hepatitis C is caused
121 II, 6. 3. 6| of the years include both E. coli and VTEC. The most
122 II, 6. 4. 5| immunization programmes; e) reinforce the food monitoring
123 II, 7. 7 | Holder Y, Peden M, Krug E (Eds.) (2001): Injury Surveillance
124 II, 8. 2. 1| 50 (9), 667–677.~Emerson, E. (2005) Underweight, obesity
125 II, 8. 2. 1| Research 49, 134–143.~Emerson, E. and Hatton, C. (2007a).
126 II, 8. 2. 1| Retardation 112, 140-150.~Emerson, E. and Hatton, C. (2007b).
127 II, 8. 2. 1| Bradley,V., Buntinx, W.H.E., Coulter, D.L., Craig,
128 II, 8. 2. 1| Y., Reeve, A., Snell, M.E., Spreat, S., Tasse, M.J.,
129 II, 9. 1. 1| Saigal S, Nimrod C, Kelly E, et al (2002): Neonatal
130 II, 9. 1. 1| 2004;191(3):700-7.~Garne E (2001): Perinatal mortality
131 II, 9. 1. 1| PA, Bakoula C, Hemminki E, Knudsen L, Levasseur M,
132 II, 9. 1. 2| congenital heart disease) and e) practices regarding registration
133 II, 9. 1. 2| risk factor information e) full information on terminations
134 II, 9. 1. 2| environmental pollution.~ ~e) Public health measures
135 II, 9. 1. 2| Ritvanen A, Robert-Gnansia E, Siffel C, Stoll C and Mastroiacovo
136 II, 9. 1. 2| R, Scarano G, Calzolari E, Neville A, Cocchi G, Bianca
137 II, 9. 1. 2| Ritvanen A, Robert-Gnansia E, Daltveit, A, Aneren G,
138 II, 9. 1. 2| S, Bianchi F, Calzolari E, De Walle H, Knill-Jones
139 II, 9. 1. 2| Dolk H, Loane M, Garne E, de Walle, H, Queisser-LuftA,
140 II, 9. 1. 2| Vigan C, de Walle H, Garne E, Loane M, Pierini A, Garcia-Minaur
141 II, 9. 1. 2| Tenconi R, Wiesel A, Calzolari E, Stone D (2004): "Towards
142 II, 9. 1. 2| 45, No 1, pp 52-58.~Garne E, Loane M, Nelen V, Bakker
143 II, 9. 1. 2| Vol 2, pp 165-169.~Garne E, Loane M, Dolk H, de Vigan
144 II, 9. 1. 2| Vol 25, pp 6-11.~Garne E, Loane M, de Vigan C et
145 II, 9. 1. 2| Vol 24, pp 908-12.~Garne E et al (1999): "Congenital
146 II, 9. 1. 2| Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ (
147 II, 9. 1. 2| McElhatton P, Reuvers M, Robert E, Rost van Tonningen M, Scialli
148 II, 9. 1. 2| D, Abramsky L, Alberman E, Scott JES (2000): “Socioeconomic
149 II, 9. 2. 7| Levi F, La Vecchia C, Negri E, Lucchini F (2001): Childhood
150 II, 9. 2. 7| Ståhl T, Wismar M, Ollila E, Lahtinen E, Leppo K (eds.) (
151 II, 9. 2. 7| Wismar M, Ollila E, Lahtinen E, Leppo K (eds.) (2006):
152 II, 9. 3. 1| 009415~ ~Forsgren L, Beghi E, Õun A, Sillanpää M (2005):
153 II, 9. 3. 1| 1992Impotence091html.htm~ ~Niederlaender E (2006): Causes of death
154 II, 9. 3. 1| 2006~ ~Plümper T, Neumayer E (2006): The unequal burden
155 II, 9. 3. 2| Saigal S, Nimrod C, Kelly E, et al (2002): Neonatal
156 II, 9. 3. 2| 2004;191(3):700-7.~ ~Garne E (2001): Perinatal mortality
157 II, 9. 3. 2| PA, Bakoula C, Hemminki E, Knudsen L, Levasseur M,
158 II, 9. 3. 3| gender-related issues” (e.g.violence).~ ~On 3 July
159 II, 9. 3. 3| Dubois-Arber F, Jeannin A, Konings E, Paccaud F (1997): Increased
160 II, 9. 3. 3| Official Journal C 271 E , 12/11/2003 P. 0369 - 0374~
161 II, 9. 3. 3| 26:319-39.~Haavio-Mannila E, Kontula O (2001): Seksin
162 II, 9. 3. 3| Helsinki:WSOY.~Haavio-Mannila E, Kontula O (2003) Sexual
163 II, 9. 3. 3| Kaponen P, Haavio-Mannila E, Hemminki E (2007): Sexual
164 II, 9. 3. 3| Haavio-Mannila E, Hemminki E (2007): Sexual health among
165 II, 9. 3. 3| Pasquarella C, Limina RM, Cozani E, Fanti M, Cielo A, Greco
166 II, 9. 3. 3| Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel
167 II, 9. 4. 7| Jassem J, Senkus-Konefka E (2004): Report on 4th European
168 II, 9. 4. 7| 2)~ ~Mukaetova-Ladinska E (2006): Towards living long
169 II, 9. 5. 6| 1), pp. 47-59.~ ~Probyn E (2000): Sporting Bodies:
170 II, 9. 5. 6| Risberg G, Hamber K, Johansson E (2006): Gender perspective
171 III, 10. 1. 3| 29(8):1076-1089.~Kuntsche E, Jordan MD (2006): Adolescent
172 III, 10. 1. 3| Ashley MJ, Room R, Single E, Bondy S, Ferrence R, Giesbrecht
173 III, 10. 2. 1| Ringborg U, Scully C, Siracka E, Storm H, Tubiana M, Tursz
174 III, 10. 2. 1| Holder HD, Homel R, Österberg E, Rehm J, Room R and Rossow
175 III, 10. 2. 1| Lushey C, Morleo M, Stokes E, Sumnall H, Witty K, Bellis
176 III, 10. 2. 1| F, Dickinson HO, Pienaar E, Campbell F, Schlesinger
177 III, 10. 2. 1| Koivusilta L, Honkala S, Honkala E, Rimpelä A (2003): Toothbrushing
178 III, 10. 2. 1| http://www.who.int/gb/e/e_wha60.html] (accessed
179 III, 10. 2. 1| http://www.who.int/gb/e/e_wha60.html] (accessed on
180 III, 10. 2. 1| activity are still rare.~ ~e) Data from accession countries~
181 III, 10. 2. 1| Saba A, Perrone D, Cialfa E, D'Amicis A (2001): Food
182 III, 10. 2. 1| physical activity (OJ C 250 E, 25.10.2007, p. 93~· White
183 III, 10. 2. 1| only 7 are the same (i. e.: eat plenty of).~Two approaches
184 III, 10. 2. 1| Demarest S, Gisle L, Hesse E, Miermans PJ, Tafforeau
185 III, 10. 2. 1| Scarpino V, Zuccaro P, Negri E, Apolone G, La Vecchia C (
186 III, 10. 2. 1| Petkevičienė J, Šakytė E, Kriaučionienė V, Paalanen
187 III, 10. 2. 1| nì Mhurchu C, Kalamara E, Shayeghi M, Rigby NJ, Nishida
188 III, 10. 2. 1| October 2007).~ ~Johannsson E, Arngrimsson SA, Thorsdottir
189 III, 10. 2. 1| Jotangia D, Moody A, Stamatakis E, Wardle H (2005): Obesity
190 III, 10. 2. 1| 112:1431–1433.~ ~Kapantais E, Haralambides V, Tzotzas
191 III, 10. 2. 1| Suppl. 1):S71.~ ~Kapantais E, Tzotzas E, Loannidis I,
192 III, 10. 2. 1| Kapantais E, Tzotzas E, Loannidis I, Mortoglou
193 III, 10. 2. 1| Agoston H, Balázs A, Mozsáry E, Vitrai J, Hermann D, Boros
194 III, 10. 2. 1| Panagi A, Chrictodoulou E, Kafatos A (2005): Prevalence
195 III, 10. 2. 1| 105:260–275.~ ~Stamatakis E, Primatesta P, Chinn S,
196 III, 10. 2. 1| Chinn S, Rona R, Falascheti E (2005): Overweight and obesity
197 III, 10. 2. 1| Summerbell C, Waters E, Edmunds LD, Kelly S, Brown
198 III, 10. 2. 1| 726.~ ~Szponar L, Rychlik E, Oltarzewski Ml (2003):
199 III, 10. 2. 1| Szponar L, Sekula W, Rychlik E, Oltarzewski M, Figurska
200 III, 10. 2. 1| ece/ac/ece.ac.21.2002.9.e.pdf).~ ~Visscher TLS, Viet
201 III, 10. 2. 1| Elmadfa I, Weichselbaum E (eds) (2005): European Nutrition
202 III, 10. 2. 1| Zhang JX, Welch AA, Spencer E, Stripp C, Overvad K, Clavel-Chapelon
203 III, 10. 2. 1| F, Casagrande C, Riboli E (2002): Consumption of vegetables,
204 III, 10. 2. 1| Lagiou A, Slimani N, Lund E, Chirlaque MD, Vasilopoulou
205 III, 10. 2. 1| Chirlaque MD, Vasilopoulou E, Zavitsanos X, Berrino F,
206 III, 10. 2. 1| Schulz M, Hemon B, Riboli E (2002): Consumption of dairy
207 III, 10. 2. 1| Slimani N, Mattisson I, Lundin E, McTaggart A, Allen NE,
208 III, 10. 2. 1| Skeie G, Tormo MJ, Ardanaz E, Charrondiere UR, Riboli
209 III, 10. 2. 1| Charrondiere UR, Riboli E (2002): Soy product consumption
210 III, 10. 2. 1| Linseisen J, Bergstrom E, Gafa L, Gonzalez CA, Thiebaut
211 III, 10. 2. 1| Clavel-Chapelon F, Kesse E, Miller AB, Schulz M, Botsi
212 III, 10. 2. 1| 1242.~ ~Linseisen J, Kesse E, Slimani N, Bueno-De-Mesquita
213 III, 10. 2. 1| Giurdanella MC, Norat T, Riboli E. (2002b): Meat consumption
214 III, 10. 2. 1| Chirlaque MD, Pozo BG, Ardanaz E, Mattisson I, Pettersson
215 III, 10. 2. 1| Clavel-Chapelon F, Kesse E, Boeing H, Klipstein-Grobusch
216 III, 10. 2. 1| Trichopoulou A, Vasilopoulou E, Bellos G, Pala V, Masala
217 III, 10. 2. 1| Skeie G, Slimani N, Riboli E (2006): Dietary intake of
218 III, 10. 2. 1| Sieri S, Agudo A, Kesse E, Klipstein-Grobusch K, San-Jose
219 III, 10. 2. 1| Kolyva M, Saieva C, Celentano E, Ocke MC, Peeters PH, Brustad
220 III, 10. 2. 1| Mattisson I, Weinehall L, Riboli E, Slimani N (2002): Patterns
221 III, 10. 2. 1| 1287-1296.~ ~Welch AA, Lund E, Amiano P, Dorronsoro M,
222 III, 10. 2. 4| Organisation~APOE~Apolipoprotein E~MTHFR~Meth ~ ~
223 III, 10. 2. 4| Collins FS, Patrinos A, Jordan E, Chakravarti A., Gesteland
224 III, 10. 2. 4| Johnson J, Cox N J, Wichmann H E, Wienker T F, Schulze J,
225 III, 10. 2. 4| F, Schulze J, Schwarz P E, Lindner T H (2007): A German
226 III, 10. 2. 4| Klein C, Rodriguez-Cerezo E (2003): Institute of Prospective
227 III, 10. 2. 4| MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P,
228 III, 10. 2. 4| Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong
229 III, 10. 2. 4| Vol 447:661-678~ ~Zika E, Papatryfon I, Wolf O, Gómez-Barbero
230 III, 10. 2. 5| Osmond C, Forsén TJ, Kajantie E, Eriksson JG (2005): Trajectories
231 III, 10. 2. 5| Eriksson JG, Osmond C, Kajantie E, Forsén TJ, Barker DJP (
232 III, 10. 3. 1| Ruano-Ravina A, Ruosteenoja E, A Schaffrath Rosario A,
233 III, 10. 3. 1| Tirmarche M, Tomáek L, Whitley E, Wichmann HE, Doll R, (2005):
234 III, 10. 4. 2| irradiation of foodstuffs; e) RASFF and emergencies:
235 III, 10. 4. 2| including Verotoxigenic E. coli;~• Campylobacter;~•
236 III, 10. 4. 2| Shellfish~Hepatitis E virus~ ~ ~Pig~ ~ ~ ~Table
237 III, 10. 4. 2| High, in adults~Hepatitis E virus~ ~Jaundice~ ~High,
238 III, 10. 4. 2| facilities and equipment; (e) that they have the legal
239 III, 10. 4. 2| Autoridade de Segurança Alimentar e Económica~Portugal~The nd~
240 III, 10. 4. 5| for faecal contamination, E. Coli and Intestinal Enterococci,
241 III, 10. 4. 5| have been simplified to E. coli and intestinal enterococci,
242 III, 10. 5. 1| Bygren, L O. Johansson, S E. Visiting the cinema, concerts,
243 III, 10. 5. 1| Rogers MAM, Zaragoza-Lao E: Happiness and children’
244 III, 10. 5. 1| 2001, S. II-10~Shenassa, E., Liebhaber, A., Ezeamama,
245 III, 10. 5. 1| aria nelle scuole europee e sue implicazioni sulla salute
246 III, 10. 5. 2| on 2 August 2007).~ ~Roel E et al. (2005): Clinically
247 III, 10. 6. 1| Currie C, Gabhainn S, Godeau E, Roberts C, Smith R, Currie
248 III, 10. 6. 1| R, McLeod J, Wethington E. The cost of caring: a perspective
249 III, 10. 6. 1| ahead of print]~Shenassa, E., Liebhaber, A., Ezeamama,
250 III, 10. 6. 2| Kunst AE, Borrell C, Breeze E, Cambois E, Costa G, Geurts
251 III, 10. 6. 2| Borrell C, Breeze E, Cambois E, Costa G, Geurts JJM, Lahelma
252 III, 10. 6. 2| Costa G, Geurts JJM, Lahelma E, Van Oyen H, Rasmussen NK,
253 III, 10. 6. 2| H, Rasmussen NK, Regidor E, Spadea T, and Mackenbach
254 IV, 11. 5. 5| written by Michel Goldman e Kathryn Wood (Goldman and
255 IV, 11. 6. 5| 13-16.~ ~Brook R, McGlynn E et al. (1996): "Quality
256 IV, 11. 6. 5| Culyer AJ, Doorslaer E et al. (1992): "Comment:
257 IV, 11. 6. 5| University.~ ~Ettelt S, Nolte E et al. (2006): Health care
258 IV, 11. 6. 5| Kanavos P, Mossialos E (1999): "International comparisons
259 IV, 11. 6. 5| Policy 4(2): 122-6.~ ~Kelley E, Hurst J (2006): Health
260 IV, 11. 6. 5| Community. W.W. Holland and E. Mossialos. Aldershot: Ashgate~ ~
261 IV, 11. 6. 5| 11: 199–205.~ ~Mossialos E, Brogan D et al. (2006): "
262 IV, 11. 6. 5| 59(3): 3-25.~ ~Mossialos E, Merkur S et al. (2006):
263 IV, 11. 6. 5| Institutions.~ ~Mossialos E, Dixon A Eds. (2002): Funding
264 IV, 11. 6. 5| and Policies.~ ~Mossialos E, Dixon A et al. (2000): "
265 IV, 11. 6. 5| 320: 197-8.~ ~Mossialos E, Le Grand J Eds. (1999):
266 IV, 11. 6. 5| Aldershot.~ ~Mossialos E, Mrazek M et al. (2004):
267 IV, 11. 6. 5| Pharmaceuticals in Europe. E. Mossialos, M. Mrazek and
268 IV, 11. 6. 5| University Press.~ ~Mossialos E, Thomson S (2004): Voluntary
269 IV, 11. 6. 5| and Policies.~ ~Mossialos E, Walley T et al. (2004):
270 IV, 11. 6. 5| efficiency, equity and quality. E. Mossialos, T. Walley and
271 IV, 11. 6. 5| and Policies.~ ~Mossialos E, Walley T et al. (2005): "
272 IV, 11. 6. 5| 93.~ ~Mrazek M, Mossialos E (2004): Regulating pharmaceutical
273 IV, 11. 6. 5| efficiency, equity and quality. E. Mossialos, M. Mrazek and
274 IV, 11. 6. 5| and development.~ ~Nolte E, McKee M (2005): Does Health
275 IV, 11. 6. 5| Trust~ ~Oliver A, Mossialos E (2004): "Equity of access
276 IV, 11. 6. 5| Perleth M, Jakubowski E et al. (2001): "What is '
277 IV, 11. 6. 5| care: options for Europe. E. Mossialos, A. Dixon, J.
278 IV, 11. 6. 5| care: options for Europe. E. Mossialos, A. Dixon, J.
279 IV, 11. 6. 5| Robinson R, Jakubowski E et al. (2005): Organization
280 IV, 11. 6. 5| Figueras, R. Robinson and E. Jakubowski. Copenhagen,
281 IV, 11. 6. 5| Thomson S, Mossialos E et al. (2003): Cost sharing
282 IV, 11. 6. 5| Thomson S, Mossialos E et al. (2004): Health and
283 IV, 11. 6. 5| 75-98.~ ~van Doorslaer E, Koolman X et al. (2004): "
284 IV, 11. 6. 5| 629-647.~ ~van Doorslaer E, Masseria C et al. (2004):
285 IV, 11. 6. 5| Paris, OECD.~ ~Van Doorslaer E, Wagstaff A et al. (1999): "
286 IV, 11. 6. 5| Wagstaff A, van Doorslaer E et al., Eds. (1999): Equity
287 IV, 11. 6. 5| Press.~ ~Walley T, Mossialos E (2004): Financial incentives
288 IV, 11. 6. 5| Pharmaceuticals in Europe. E. Mossialos, M. Mrazek and
289 IV, 12. 1 | in Articles 3, where the E.U., is to make “a contribution
290 IV, 12. 1 | protection” (art.3p) in pursuing E.U. priority objectives and
291 IV, 12. 5 | data)~- Disease registers (e. g. cancer, myocardial infarction,
292 IV, 12. 5 | stroke)~- Sentinel Networks (e. g. diseases not under mandatory
293 IV, 12. 5 | Active Surveillance Measures(e. g. Notifiable Infectious
294 IV, 12. 5 | Administrative data (e. g. health insurance data,
295 IV, 12. 5 | care staff)~- Process data (e. g. data on health care
296 IV, 12. 5 | studies~- Data from Surveys (e. g. population representative
297 IV, 12. 10 | FA C T S A N D A D V I C E~about smoking and stopping~http df~
298 IV, 12. 10 | some cases federal) laws e. g. against smoking at public
299 IV, 12. 10 | children/adolescents (see e. g. www o) including quit-lines (
300 IV, 12. 10 | non-governmental organisations (e. g. German Medical Association/
301 IV, 12. 10 | since 2004): targets e. g. prevention of diabetes
302 IV, 12. 10 | improved local infrastructure (e. g. cycle paths, public
303 IV, 12. 10 | self-help organizations (e. g. drug counselling centres).~ ~
304 IV, 12. 10 | different sorts of drugs (e. g. “Quit the shit”-program
305 IV, 12. 10 | focus on health behaviour (e. g. information concerning
306 IV, 12. 10 | ionising radiation there are, e. g., X-ray diagnostics in
307 IV, 12. 10 | implemented early warning systems (e. g. on heat waves) that
308 IV, 12. 10 | in sozialen Brennpunkten E&C) htt ; In cooperation
309 IV, 12. 10 | additional information see e. g. German Registry for
310 IV, 12. 10 | bioethical subjects see e. g. Federal Ministry of
311 IV, 12. 10 | Ministerial Decision 37411/1829/E 103 defining the relevant
312 IV, 12. 10 | been partly funded by the E.U~o Common Ministerial Decision
313 IV, 12. 10 | control in compliance with the E.U Regulation 93/99.~o Common
314 IV, 13.Acr | Quality Adjusted Life Years~S&E~Science and Engineering~ ~ ~
315 IV, 13. 7. 2| science and engineering (S&E) graduates, who now make
316 IV, 13. 7. 2| stronger performance in S&E graduates and broadband
317 IV, 13. 9 | 2002; 360: 1347-60.~Fazi E, Smith J (2006): Civil Dialogue:
|
|
| |
